Heron Therapeutics (NASDAQ:HRTX) has been assigned a $34.00 price objective by Oppenheimer in a research report issued to clients and investors on Monday, March 19th. The firm currently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price target indicates a potential upside of 16.84% from the company’s current price. Oppenheimer also issued estimates for Heron Therapeutics’ FY2019 earnings at ($0.23) EPS, FY2020 earnings at $1.22 EPS, FY2021 earnings at $3.30 EPS and FY2022 earnings at $5.03 EPS.
A number of other analysts have also weighed in on the stock. Mizuho reiterated a “buy” rating and issued a $28.00 price objective on shares of Heron Therapeutics in a research note on Friday, December 8th. Cantor Fitzgerald set a $31.00 price objective on shares of Heron Therapeutics and gave the stock a “buy” rating in a research note on Monday, January 15th. BidaskClub raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 20th. ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Zacks Investment Research downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $35.92.
Shares of Heron Therapeutics stock opened at $29.10 on Monday. Heron Therapeutics has a 12-month low of $12.70 and a 12-month high of $32.70. The company has a market cap of $1,888.80, a price-to-earnings ratio of 7.97 and a beta of 1.86.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.29). The business had revenue of $10.05 million during the quarter, compared to analyst estimates of $9.00 million. Heron Therapeutics had a negative return on equity of 230.70% and a negative net margin of 641.87%. equities research analysts expect that Heron Therapeutics will post -2.5 earnings per share for the current fiscal year.
In other news, VP Kimberly Manhard sold 18,000 shares of the firm’s stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $30.00, for a total value of $540,000.00. Following the transaction, the vice president now directly owns 18,000 shares of the company’s stock, valued at $540,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kevin C. Tang acquired 192,308 shares of the business’s stock in a transaction that occurred on Thursday, March 29th. The shares were purchased at an average price of $26.00 per share, with a total value of $5,000,008.00. The disclosure for this purchase can be found here. Over the last three months, insiders sold 218,000 shares of company stock worth $5,990,000. Insiders own 19.93% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Ellington Management Group LLC acquired a new stake in Heron Therapeutics during the fourth quarter worth about $195,000. Pinnacle Associates Ltd. acquired a new stake in Heron Therapeutics during the fourth quarter worth about $201,000. Trexquant Investment LP acquired a new stake in shares of Heron Therapeutics during the third quarter valued at about $206,000. Jefferies Group LLC acquired a new stake in shares of Heron Therapeutics during the fourth quarter valued at about $214,000. Finally, Jane Street Group LLC acquired a new stake in shares of Heron Therapeutics during the third quarter valued at about $223,000. Hedge funds and other institutional investors own 97.40% of the company’s stock.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.